Wound dressings CHX-HMP



The aim is to develop a novel wound dressing augmented with a novel antimicrobial material. The focus of this proof-of-principle study will be intravenous securement dressings used to protect venous catheter entry sites. The development of wound care product with sustained antimicrobial efficacy has applications beyond any one clinical application and will be of interest to manufacturers and researchers in areas such as diabetic foot care, burns treatment and other chronic wounds.

Chronic wounds are prone to infection and are associated with the presence of biofilm, which is inherently difficult to treat. Catheters are responsible for the largest proportion of healthcare-associated BSIs. Catheter-related BSIs lead to delays in treatment for the underlying condition and may result in serious illness or death. Catheter entry sites are protected by dressings, but these are typically changed weekly and may act as reservoirs for bacteria which then colonise the catheter itself.

Antibiotics are still regarded as a front line treatment for many bacterial infections. Longstanding use has led to a number of important pathogens developing antibiotic resistance. This compromises ongoing antibiotic prescription, since this exacerbates the problem and may lead to recurrent infection. Thus there is interest in non-antibiotic methods for addressing this clinical need. CHX is a broad spectrum biocide, meaning that it is effective against a wide range of microorganisms and has a mode of action which is less susceptible to evolution of bacterial resistance. CHX-containing wound products are available, such as gels, rinses and CHX-impregnated dressings but the active CHX is depleted rapidly and the antimicrobial environment is thus not sustained for as long as the clinician would wish.
Date made available24 Jun 2016
PublisherUniversity of Bristol


  • antimicrobials
  • Biomaterials

Cite this